Combination therapy for glaucoma

Abstract

Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α 2 -selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca 2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.

1 . A method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α 2 -selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca 2+  channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. 
     
     
         2 . The method of  claim 1  wherein the prostaglandin agonist and the second therapeutically active agent are administered in separate dosage forms. 
     
     
         3 . The method of  claim 1  wherein the prostaglandin agonist and the second therapeutically active agent are administered in a single dosage form. 
     
     
         4 . The method of  claim 1  or  2  wherein the prostaglandin agonist is a selective agonist of the prostaglandin EP2 or prostaglandin EP4 receptor. 
     
     
         5 . The method of  claim 1  or  2  wherein the prostaglandin agonist is a compound selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or is a C 1-6  alkyl ester, a phenyl ester, a 2-hydroxyethyl ester, or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         7 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         8 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         9 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         10 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         11 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       
         
       
     
     
         12 .  or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         13 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         14 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         15 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         16 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         17 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         18 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         19 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         20 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         21 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         22 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         23 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof. 
     
     
         24 . The method of  claim 5  wherein the prostaglandin agonist is 
       
         
           
           
               
               
           
         
       
       or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof.